A major pathogenetic mechanism in classical Hodgkin lymphoma (cHL) is constitutive activation of canonical nuclear factor-jB (NF-jB) p50/p65 signaling, controlling lymphoma cell proliferation and survival. Recently, we demonstrated that aberrant Notch1 activity is a negative regulator of the B cell program in B cell-derived Hodgkin and Reed-Sternberg (HRS) cells. Despite abundant evidence for a complex contextdependent cross talk between Notch and NF-jB signaling in hematopoietic cells, it is unknown whether these pathways interact in HRS cells. Here, we show that Notch-signaling inhibition in HRS cells by the c-secretase inhibitor (GSI) XII results in decreased alternative p52/RelB NF-jB signaling, interfering with processing of the NF-jB2 gene product p100 into its active form p52. As a result, expression of Notch and NF-jB target genes is reduced, and survival of HRS cells is impaired. Stimulation of alternative NF-jB signaling in the Hodgkin cell line L540cy by activation of the CD30 receptor rescued GSI-mediated loss of cell viability and apoptosis induction. Our data reveal that Notch is an essential upstream regulator of alternative NF-jB signaling and indicate cross talk between both the pathways in HRS cells. Therefore, we suggest that targeting the Notch pathway is a promising therapeutic option in cHL.
Introduction
The Notch signaling pathway has been implicated in developmental and differentiation processes, proliferation and apoptosis, as well as cancer progression. 1 Upon ligand binding, the transmembrane/cytoplasmic portion of the Notch1 receptor (Notch1) is cleaved by the g-secretase complex and the intracellular part (Notch1 IC ) is released.
1 Notch1 IC then translocates into the nucleus to act as a switch for the transcription factor RBP-Jk, which binds to responsive elements and represses target genes. 1 During lymphocyte development Notch1 acts as a T-cell transcription factor that suppresses B cell development and promotes T-cell development. 2 We have shown earlier that the Notch family members Notch1 and Notch2 are aberrantly expressed in Hodgkin and Reed-Sternberg (HRS) cells, and that external stimulation of Notch signaling in HRS cells through the Notch ligand Jagged1 promotes their proliferation and protects them from arsenic-induced apoptosis.
3 Jagged1 is expressed in HRS cells and bystander cells in vivo, 3 and the Notch ligands of the Delta-like family (DLL1, DLL3, DLL4) and Jagged2 are expressed in cultured HRS cells to activate Notch signaling. 4 We further demonstrated that absence of the main Notch1 inhibitor Deltex1 and high-level expression of the Notch co-activator of the Mastermind-like family contribute to deregulated Notch signaling in HRS cells. 4, 5 Notch1 activity reduces the expression of the B cell transcription factors E12 and E47, and EBF1 and induces the transcription of activated B cell factor 1 (ABF-1). 5 In addition, Notch1 binds to PAX5 in HRS cells, which might impair PAX5 function. 5 Therefore, aberrant expression of this master regulator of T-cell development may contribute to loss of the B cell phenotype and expression of T-cell-specific genes in classical Hodgkin lymphoma (cHL). 5 Despite abundant evidence for a complex context-dependent cross talk between Notch1 and nuclear factor-kB (NF-kB) signaling in hematopoietic cells, 6 it remains elusive whether aberrant Notch activity interferes with the major pathogenetic mechanism in cHL: constitutive activation of the NF-kB signaling pathway.
Recently, we provided evidence that HRS cells are characterized by high levels of nuclear NF-kB p50/p65 dimers, 7 required for their proliferation and protection from apoptosis, as well as for HRS cell growth in mouse lymphoma models. 8, 9 Moreover, we showed that deactivating mutations in the genes of the NF-kB inhibitors IkBa and IkBe 10, 11 or aberrant activity of the IkB protein kinase (IKK)a, 12 contribute to constitutive activation of the canonical NF-kB pathway in HRS cells. In addition, activation of the NF-kB pathway in HRS cells can be mediated by signaling through the tumor necrosis factor (TNF) receptor family members CD30, CD40, receptor activator of NF-kB (RANK), BCMA, TACI or through Epstein-Barr virus-encoded latent membrane protein 1. 13, 14 Furthermore, genetic lesions, including genomic Rel amplification, inactivating mutations of tumor necrosis factor AIP3 and BCL3 gains or translocation are involved in constitutive NF-kB activation in HRS cells. 14 Whereas the pathogenetic role of the canonical NF-kB pathway is well characterized, only three reports suggest that components of the alternative pathway are overexpressed in HRS cells: (1) NF-kB2 p100/p52 and RelB, and (2) NIK (NF-kB-inducing kinase). [15] [16] [17] Moreover, it has been demonstrated that stimulation of CD30 signaling either by agonistic receptor antibodies or by CD30 ligand induces alternative NF-kB signaling in HRS cells. 18, 19 However, one study showed that CD30 signaling is absent in HRS cells. 20 Therefore, it remains largely unknown how the alternative NF-kB pathway is activated and whether it has a functional role in HRS cell growth and survival.
Cross talk between NF-kB and Notch1 in hematopoietic cells involves context-dependent mechanisms: (1) in murine hematopoietic precursors Notch1 transcriptionally induces p50, p65, RelB and c-Rel expression; 6 (2) in Jurkat T-acute lymphoblastic leukemia (T-ALL) cells the p100 promoter is transcriptionally activated by a RBP-Jk-responsive element that overlaps with a kB site; 6 (3) vice versa, in B cells, NF-kB transcriptionally activates the Notch ligand Jagged-1; and (4) physical interaction between Notch and NF-kB pathway members has been described in murine as well as Jurkat T-ALL cells. 6 In this study, we used the g-secretase inhibitor (GSI) XII for blockage of Notch activity to analyze potential cross talk between Notch and NF-kB signaling pathways in HRS cells.
Materials and methods

Cell culture and reagents
Human Hodgkin and Burkitt lymphoma cell lines (HDLM-2, HD-MY-Z, KM-H2, L591, L1236, L428, L540cy, BJAB), hepatocellular carcinoma HEP-G2 cells and murine fibroblast NIH-3T3 cells were used (DSMZ, Braunschweig, Germany). GSI XII was obtained from Calbiochem (San Diego, CA, USA). For anti-CD30 stimulation, plates were coated with 10 mg/ml anti-CD30 antibodies (clone 81337, R&D Systems, Wiesbaden, Germany) overnight at 4 1C. Before plating of the cell suspension, plates were washed and blocked with 5 mg/ml bovine serum albumin. GSI XII was added 24 h later. Conditioned medium from L540cy, L1236, KM-H2 and L428 cells was prepared after 96 h without medium change, and supplemented with nutrients and fetal calf serum.
Immunoblotting
Whole-cell extracts were prepared and immunoblotting was performed as described. 3 Nuclear extracts were prepared using the Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA). Blots Notch and NF-jB in HRS cells R Schwarzer et al were incubated with monoclonal rabbit anti-Notch1, anti-p50/ p105, anti-p65 antibodies (Epitomics, Burlingame, CA, USA), anti-cleaved Notch1, rabbit polyclonal anti-p52/p100, antiphospho-p100, anti-RelB, anti-c-Rel, anti-poly-(ADP-ribose) polymerase, anti-cleaved poly-(ADP-ribose) polymerase (Asp214) antibodies (Cell Signaling Technologies, Frankfurt, Germany), anti-human CD30 (R&D Systems) or mouse monoclonal anti-tubulin antibodies (Sigma, Deisenhofen, Germany). Detection was performed using Pico or Dura chemiluminescence reagents (Perbio Science, Bonn, Germany).
RNA preparation, semi-quantitative and quantitative reverse transcription-PCR analysis
RNA preparation and complementary DNA synthesis were performed as described. 5 Reverse transcription-PCR analysis was performed as described using primers and probes for human HEY1, ABF-1, CCR7, c-IAP2. 5 As an internal control human b-actin was amplified. Primer sequences are available upon request.
Viability assay and assessment of apoptosis
Viability of cells was determined by CellTiter-Glo Luminescent Cell Viability Assay (Promega, Mannheim, Germany). Each treatment was done in four independent replicates. Luminescence was recorded; average values were calculated and normalized to the respective DMSO-treated sample. Amount of apoptotic cells was determined using human AnnexinV-FITC Kit (Bender Medsystems, Vienna, Austria).
Dual-luciferase reporter assays and NF-kB transcription factor DNA-binding assays
For the NF-kB reporter assay, cells were electroporated with 6X-kB firefly Luciferase construct (10 mg) 21 together with 5 mg of pRL-TKLuc (Renilla luciferase) as an internal control. At 24 h after transfection, cells were treated with GSI XII or DMSO. After 24 h, cells were lysed and the ratio of the two luciferases was determined with Dual-Glo luciferase kit (Promega). Levels of nuclear DNA-binding NF-kB subunits were assessed using the TransAM NF-kB Family Kit (Active Motif). Fractionated protein lysates were prepared and nuclear fraction was incubated on a 96-well plate containing immobilized kB-consensus oligonucleotides. Bound NF-kB complexes were detected using specific antibodies directed against the different subunits, and quantified using horseradish peroxidase-based colorimetric readout.
Results
Notch inhibition controls the survival of HRS cells
In this study, we analyzed inhibition of Notch activity and treated cultured HRS cells with GSI XII. The latter interferes with the g-secretase complex, and has been used both in vivo and in vitro. 22 As shown in Figure 1a , Notch1 was highly expressed in most cultured HRS cells (except in L1236 cells) as previously described. 3 The control cell lines (HEP-G2: hepatocellular carcinoma cells and BJAB: Burkitt lymphoma cells) also expressed significant amounts of Notch1, whereas NIH-3T3 mouse embryonic fibroblasts revealed undetectable levels of Notch1. In addition, we recently demonstrated that all cultured HRS cells and the Burkitt lymphoma cell line BJAB express variable levels of Notch1 IC . 4 However, neither Notch1 nor Notch1 IC levels alone predict the functional activity of the Notch transcriptional complex. 4 Therefore, we determined the activity of the Notch transcriptional complex by analyzing Notch target gene expression (ABF-1 (refs 5,23) and
, using semi-quantitative reverse transcription-PCR analysis (Figure 1a , lower panel). Our previous data demonstrated that the E2A antagonist ABF-1 is overexpressed in HRS cells, and we identified ABF-1 as a Notch1-specific target gene using siRNA against Notch1.
5,23 ABF-1 and/or HEY1 were (Figure 1b , lower panel) after GSI XII treatment in HRS cells, and showed dose-dependent downregulation. Although we cannot formally rule out off-target effects of GSI XII in HRS cells, these data here confirm our recent results showing transcriptional downregulation of ABF-1 in HRS cells after siRNA-mediated suppression of Notch1. 5 Our data indicate that Notch signaling is constitutively active in HRS cells and is efficiently blocked by GSI XII.
To investigate the biological significance of Notch inhibition, we treated HRS and control cell lines with GSI XII, and measured cell viability using the CellTiter-Glo assay (Promega) (Figure 1c ). We observed highly sensitive (KM-H2, L1236, L540cy) or sensitive (HDMyZ, HDLM2, L591) HRS cells and resistant L428 cells (Figure 1c ). The control cell lines (NIH-3T3, HEP-G2 BJAB) were almost unaffected by GSI treatment, thus excluding unspecific toxicity of the inhibitor (Figure 1c 
Notch inhibition reduces NF-kB transcriptional activity in L540cy cells
Our previous studies provided evidence that HRS cell survival critically depends on constitutive NF-kB activation.
8,9,17 Therefore, we analyzed potential cross talk between Notch and NF-kB in HRS cells. Transcriptional NF-kB activity was analyzed after Notch-inhibition employing reporter constructs. These constructs contain six kB motifs upstream of the firefly luciferase gene. As shown in Figure 3a , GSI treatment led to a dose-dependent reduction of NF-kB reporter activity in L540cy cells. Already 2 mM GSI XII caused significant changes in NF-kB transcriptional activity (Figure 3a) . In addition, expression of the NF-kB target genes CCR7 and c-IAP2, which we described in HRS cells previously, 9 was dose-dependently reduced in L540cy cells, as evidenced by quantitative reverse transcription-PCR analysis (Figure 3b) . Also, resistant L428 cells revealed no change in CCR7 and c-IAP2 mRNA levels (Figure 3b ). Our data show that Notch inhibition interferes with NF-kB-dependent gene expression in L540cy cells.
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Notch inhibition regulates alternative NF-kB activity in HRS cells
Next, we quantitatively analyzed the changes in DNA binding activity of the different NF-kB subunits after GSI treatment in HRS cells (Figure 3c ). To that end, nuclear protein samples were prepared, and proteins binding to NF-kB responsive DNA oligonucleotides were analyzed with the TransAM NF-kB family kit (Active Motif). Strongest reduction of DNA binding activity was observed for the p52 and RelB subunits in GSI sensitive L540cy, L1236 cells (Figure 3c and Supplementary Figure S1 ). As expected, DNA binding activity was not significantly reduced in resistant L428 cells. Analysis of nuclear NF-kB protein levels by immunoblotting confirmed our findings in L540cy cells (Figure 4a ). The NF-kB subunits p50, p52, p65 and RelB showed strong nuclear expression (Figure 4a ) consistent with previously described constitutive NF-kB activation in HRS cells. 7, 15, 17 Even low-dose GSI treatment resulted in strongly reduced nuclear levels, predominantly of the subunits p52 and RelB, consistent with their decreased DNA binding activity (Figure 4a ). The p52/RelB heterodimers are effectors of the alternative NF-kB signaling pathway, and their aberrant expression has been described in HRS cells previously. 15 Activation of this pathway leads to phosphorylation of p100 (p-p100) via NIK and IKKa, and its subsequent processing into p52, which heterodimerizes with RelB. 24 In order to verify that Notch inhibition regulates alternative NF-kB signaling, we analyzed phosphorylation of p100 in L540cy cells treated with GSI XII (Figure 4b ). As expected, we detected strong p100 phosphorylation in L540cy cells, confirming constitutive alternative NF-kB signaling. Furthermore, the phosphorylated form of p100 was dose-dependently reduced after GSI treatment along with decreased p52 levels (Figure 4b) . We further detected a slight increase in p100 levels, and unchanged levels of p50 and its precursor p105 (Figure 4b) . Furthermore, all cultured HRS cells displayed high levels of p-p100 (Figure 4c , upper panel), indicating constitutive alternative NF-kB signaling, but only in those that were sensitive to GSI treatment (Figure 1c ) was p-p100 concomitantly with p52 reduced upon treatment (Figure 4c, lower panel) . Our data reveal that Notch is an essential upstream regulator of alternative NF-kB signaling in HRS cells and suggest that Notch inhibition exerts its biological effects at least in part through downregulation of alternative NF-kB signaling.
Stimulation of alternative NF-kB signaling rescues HRS cells from GSI treatment
We asked whether exogenous stimulation of NF-kB signaling might rescue HRS cells from GSI treatment, to analyze the functional importance of Notch-regulated NF-kB activity. It is known that HRS cells abundantly secrete soluble factors, such as cytokines and chemokines, and that they are involved in forming the particular microenvironment in cHL, and trigger HRS cell proliferation and survival. 14, [25] [26] [27] We incubated HRS cells with fresh or conditioned medium of untreated L540cy, L1236, KM-H2 and L428 cells, and simultaneously added GSI XII for 24 h. NF-kB p52 levels, which are indicative for alternative NF-kB signaling, remained stable in L540cy cells upon stimulation of cells with conditioned medium (Figure 5a , upper panel). Accordingly, conditioned medium efficiently reversed the loss of cell viability of GSI-treated HRS cells (Figure 5a , lower panel and Supplementary Figures S2A and B) . These data indicate that HRS cells secrete factors, which activate alternative NF-kB signaling in HRS cells and contribute to HRS cell viability. Further analyses are needed to identify these factors.
To prove whether the rescue effect of secreted factors can be attributed to alternative NF-kB activation in L540cy cells, we used a defined stimulus and pre-incubated L540cy cells with agonistic CD30 antibodies overnight. It has been shown that stimulation of CD30 signaling activates alternative NF-kB signaling in HRS cells. 18, 19 As expected, NF-kB p52 levels remained stable upon GSI XII treatment in CD30-stimulated L540cy cells (Figure 5b, left panel) . As a result, loss of cell viability and apoptosis induction were alleviated in L540cy cells, as evidenced by CellTiter-Glo assay and analysis of poly-(ADP-ribose) polymerase cleavage (Figure 5b , left and right panels). Our data provide evidence that Notch is a survival factor in HRS cells, which mediates its tumor biological function partly through induction of alternative NF-kB signaling. 
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Discussion
Our results indicate that inhibition of aberrant Notch activity in HRS cells by GSI XII has potent pro-apoptotic effects through simultaneous targeting of the Notch and alternative NF-kB signaling pathways. This study confirms our previous data with multiple myeloma cell lines, and of others showing that lymphoma cell lines with activated Notch are sensitive to GSI treatment. 22, 28, 29 Recently, it has been demonstrated that in B-chronic lymphocytic leukemia cells Notch-signaling inhibition through GSI treatment accelerates B-chronic lymphocytic leukemia cell apoptosis and is accompanied by reduction of NF-kB activity, and decreased NF-kB target gene expression of c-IAP2 and XIAP. 29 Therefore, we suggest that Notch is a survival factor that exerts its effects at least in part through regulation of NF-kB in human lymphomas, such as B-chronic lymphocytic leukemia and cHL.
Our previous studies established constitutive activation of the canonical NF-kB p50/p65 signaling pathway as a major survival factor of HRS cells. [7] [8] [9] We demonstrated genetic and biochemical mechanisms of constitutive NF-kB activation, such as inactivating mutations in the main NF-kB inhibitor genes IkBa 10 and IkBe 11 or aberrant activity of IKKa. 12 Whether alternative NF-kB signaling is functionally important in HRS cells, is less clear. There are two recent reports showing that components of the alternative NF-kB pathway, p100/p52 and RelB, are overexpressed in HRS cells. 15, 17 One of these studies further provided evidence that CD30 signaling triggers alternative NF-kB signaling in rat fibroblasts 15 and two following studies confirmed that stimulation of CD30 signaling in HRS cells directly induces alternative NF-kB activation in HRS cells. 18, 19 Our data demonstrate that aberrant Notch activity is an essential upstream regulator of alternative NF-kB activation in HRS cells. GSI treatment resulted in reduced DNA binding and transcriptional activity predominantly of NF-kB p52/RelB. We show for the first time that Notch activity is involved in the activation of alternative NF-kB signaling in HRS cells via phosphorylation of p100 and subsequent processing to p52. This leads to nuclear translocation and enhanced DNA binding activity of the NF-kB heterodimers composed of p52 and RelB in HRS cells, thus Notch and NF-jB in HRS cells R Schwarzer et al directly regulating their transcriptional activity. Stimulation of CD30 signaling with agonistic antibodies prevents downregulation of NF-kB p52 and rescues GSI-treated L540cy cells. Interestingly, we obtained similar results using the tumor necrosis factor family member RANKL (RANK ligand) for activation of NF-kB in HRS cells (data not shown). RANKL is known to activate NF-kB and induces mRNA expression of cytokines and chemokines in HRS cells. 30 These data reveal as yet unknown cross talk between the NF-kB and Notch pathways in HRS cells, and provide evidence that alternative NF-kB p52/RelB is downstream of Notch.
Evidence of cross talk between Notch and NF-kB has been provided in murine hematopoietic precursor cells, normal B cells and human T-ALL cells, including mechanisms of reciprocal transcriptional regulation and physical interaction between Notch and NF-kB components, as well as binding of Notch IC to components of the IKK complex. 6 To elucidate how Notch1 mediates its effects in HRS cells, we analyzed the potential physical interaction of Notch1 and components of the alternative NF-kB pathway, such as NIK or IKKa, under basal conditions in whole-cell extracts; however, we could not detect direct binding (data not shown). Interestingly, Oswald et al. 31 demonstrated that NF-kB2 (p100/p52) is a putative Notch target gene. They showed that Notch1 IC strongly induces NF-kB2 promoter activity, and that RBP-Jk binds to the consensus sequence, 5 0 -TGGGAA-3 0 , which overlaps with kB binding sites. It might be possible that p52 expression is partly controlled through direct transcriptional regulation by the RBP-Jk/Notch complex in L540cy cells. Furthermore, Notch1 transcriptionally controls expression of the NF-kB members p50, p65, RelB and c-Rel in murine hematopoietic precursors. 6 In L540cy cells nuclear protein expression of the NF-kB members p65 and RelB is reduced after GSI treatment. Further studies are needed to clarify whether this is due to transcriptional regulation through Notch1.
Moreover, we showed that soluble factors in conditioned media of HRS cells activate alternative NF-kB signaling, and thereby rescue the anti-proliferative effects of Notch inhibition. According to the literature, there are a few candidates that have direct effects on HRS cell proliferation and survival and might be responsible for this rescue. HRS cells express the chemokine receptor CCR5 and abundantly secrete its cognate ligand CLL5. 25 In addition, signaling through the CCR5/CCL5 system regulates HRS cell growth. 25 Furthermore, interleukin 13 (IL-13) and its receptor have been shown to be frequently expressed in cultured and primary HRS cells. 27 Treatment of cultured HRS cells with IL-13-neutralizing antibodies resulted in a dosedependent proliferation arrest, indicating IL-13 involvement in HRS cell growth. 27 Similarly, IL-3 and IL-9 are functionally expressed in HRS cells and promote their proliferation. 26 Whether one of these secreted factors mediates its effects through activation of alternative NF-kB signaling in HRS cells, and whether aberrant Notch signaling might even control its expression requires further investigations.
As there is increasing evidence that Notch is an important self-renewal pathway and might have pivotal roles in so-called cancer stem cells, its inhibition seems to be a very promising strategy in cancer treatment. 32 Although the identity and origin of these cells remain controversial, they are defined as a population of cells with intrinsic ability to self-renew and to differentiate into phenotypically diverse cancer cells. 32 Therefore, Notch inhibition might not only eradicate the tumor bulk in cHL but also putative HRS precursor cells, which escape standard therapies. Recent studies showed that GSI block the activation of Notch in human T-ALL, and GSI were tested in clinical trials for their effectiveness in treating T-ALL. 33 GSI treatment was hampered by severe gastrointestinal toxicity and limited anti-leukemic efficacy. 34 However, a study in mice showed very promising results when using GSI in combination with glucocorticoids in T-ALL. 34 This combination treatment improved anti-leukemic effects and reduced their gut toxicity in vivo. 34 Similarly, glucocorticoid treatment is part of the polychemotherapy regimens used in cHL, and might be tested in future studies in combination with GSI for treatment of lymphoma patients.
